Rexulti 3 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FR0LX
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $36,112
Award facts
- Contract value 100% obligated
- $36,111.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded January 15, 2026, covers the supply of REXULTI (brexpiprazole) 3 mg tablets in a 30-count configuration to the Defense Logistics Agency (DLA) through AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract is valued at $36,111.78 with a firm fixed-price structure and represents a non-set-aside competitive award. Performance will be completed by January 16, 2026, with fulfillment occurring at the vendor's Conshohocken location. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999.99 billion vehicle that extends through December 31, 2031, and serves as the primary contracting mechanism for comprehensive pharmaceutical and medical supply support to military healthcare systems globally.
REXULTI is an atypical antipsychotic medication used in the treatment of psychiatric conditions including major depressive disorder and schizophrenia. The DLA Medical Supply Chain utilizes its extensive IDC vehicles to efficiently fulfill recurring pharmaceutical needs across military treatment facilities and veteran healthcare programs. As a leading pharmaceutical distributor with demonstrated capability to compete on a full and open basis, AmerisourceBergen maintains a critical role in supporting federal healthcare operations through the delivery of specialty medications, generic drugs, and medical commodities across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26FR0LX?
SPE2DR26FR0LX was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FR0LX worth?
The government has obligated $36,112 on SPE2DR26FR0LX.
Is contract SPE2DR26FR0LX an order under another contract?
Yes. SPE2DR26FR0LX is a delivery order under SPE2DR25D3006, an indefinite delivery contract.
Was contract SPE2DR26FR0LX competed?
The extent of competition for SPE2DR26FR0LX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award